DUBLIN , July 22, 2022 /PRNewswire/ -- The "Global COVID-19 Diagnostics Market Forecast by Technology, Product, Channel and Country: Assay Volumes and 5-Year Market Size Outlook" report has been added to ResearchAndMarkets.com's offering.
Revenue, testing volumes, technology, products and channels - they are all looked at in this complete report that provides detailed breakdowns by country and regions. Get on top of the situation quickly with market guides and situation analysis. A new dynamic market is emerging for COVID-19-based diagnostics. Testing is moving into physicians' offices and even into the home. Saliva tests? Handheld multiplex testers? Home based testing sticks? And what about the workplace market where safety is paramount? And what happens to the large laboratory capacity that was built up to handle a pandemic now in decline? Learn all about these changing markets in our latest report. Key Topics Covered:
1 Market Guides 1.1 COVID-19. Strategic Situation Analysis 1.2 COVID-19. Guidance for Executives 1.3 COVID-19. Guidance for Management Consultants and Investment Advisors
2 Introduction and Market Definition 2.1 What are Pandemics? 2.2 The Role of Zoonosis 2.3 Market Definition 2.3.1 Assay Volumes 2.3.2 PCR 2.3.3 PCR Multiplex 2.3.4 SEQ 2.3.5 Antigen 2.3.6 Antibodies 2.3.7 Instruments 2.3.8 Reagents and Kits 2.3.9 Extract 2.3.10 Collect 2.3.11 Public 2.3.12 Hospital 2.3.13 Clinic 2.3.14 Workplace 2.3.15 DTC/OTC 2.3.16 Wastewater 2.4 Methodology 2.4.1 Authors 2.4.2 Sources 2.5 Historical Perspective on Pandemics 2.5.1 HIV/AIDS Pandemic 2005-2012 2.5.2 Flu Pandemic 1968 2.5.3 Asian Flu 1956-1958 2.5.4 Spanish Flu 1918 2.5.5 Sixth Cholera Pandemic 1910-1911 2.5.6 Flu Pandemic 1889-1890 2.5.7 The Black Death 1346-1353
3 The Pandemic Overview 3.1 What is a Virus? 3.1.1 Is a Virus Alive? 3.1.2 Viral Structure 3.1.3 The Viral Genome 3.1.4 Viral Mutation 3.2 The Coronavirus 3.2.1 Severe acute respiratory syndrome (SARS) 3.2.2 Middle East respiratory syndrome (MERS) 3.2.3 COVID-19. The SARS CoV 2 Virus 3.2.3.1 Signs and symptoms 3.2.3.2 Transmission 3.2.3.3 Diagnosis 3.2.3.4 Prevention 3.2.3.5 Management 3.2.3.6 Prognosis 3.2.3.7 A Note on Global Statistics Reporting 3.3 Pandemic Diagnostics 3.3.1 Risk Management - Spark and Spread 3.3.2 Dx Technology - Nucleic Acid Based 3.3.3 Dx Technology - Immunoassay 3.3.4 Time to Market and Preparedness Issues
4 Diagnostic Company Profiles 4.1 Abacus Diagnostica 4.2 Abbott Diagnostics 4.3 Accelerate Diagnostics 4.4 Acces Bio 4.5 Advanced Biological Laboratories 4.6 Agena Bioscience, Inc 4.7 Agilent/Dako 4.8 Altona Diagnostics 4.9 Alveo Technologies 4.10 Anatolia Geneworks 4.11 Applied BioCode 4.12 Applied DNA Sciences 4.13 Assurance Scientific Laboratories 4.14 Aus Diagnostics 4.15 Autobio Diagnostics 4.16 Beckman Coulter Diagnostics 4.17 Becton, Dickinson and Company 4.18 BGI Genomics Co. Ltd 4.19 BillionToOne 4.20 Binx Health 4.21 Biocartis 4.22 Biodesix Inc 4.23 BioFire Diagnostics (bioMerieux) 4.24 Biolidics Ltd 4.25 bioMerieux Diagnostics 4.26 Bioneer Corporation 4.27 Bio-Rad Laboratories, Inc 4.28 Bio-Reference Laboratories 4.29 Bosch Healthcare Solutions GmbH 4.30 Cepheid (Danaher) 4.31 Chembio 4.32 Co Diagnostics 4.33 Color Genomics 4.34 Cue Health 4.35 Curetis N.V. / Curetis GmbH 4.36 Diagenode Diagnostics 4.37 Diasorin S.p.A 4.38 Ellume 4.39 Enzo Life Sciences, Inc 4.40 Everywell 4.41 Fluxergy 4.42 Fulgent Genetics 4.43 Fusion Genomics 4.44 Genedrive 4.45 Genetic Signatures 4.46 GenMark Dx (Roche) 4.47 Gold Standard Diagnostics 4.48 Hologic 4.49 Illumina 4.50 Immunexpress 4.51 Inflammatix 4.52 Janssen Diagnostics 4.53 Karius 4.54 Laboratory Corporation of America 4.55 Letsgetchecked 4.56 Lexagene 4.57 Luminex Corp 4.58 LumiraDx 4.59 Mammoth Biosciences 4.60 Mayo Clinic Laboratories 4.61 Mbio Diagnostics 4.62 Meridian Bioscience 4.63 Mesa Biotech (Thermo Fisher ) 4.64 Mobidiag (Hologic) 4.65 Nanomix 4.66 Novacyt 4.67 Orasure 4.68 Ortho Clinical Diagnostics 4.69 Oxford Nanopore Technologies 4.70 Perkin Elmer 4.71 Primerdesign (Novacyt) 4.72 Prominex 4.73 Qiagen Gmbh 4.74 quantumdx.com 4.75 Quest Diagnostics 4.76 Quidel 4.77 Randox Toxicology 4.78 Roche Molecular Diagnostics 4.79 SD Biosensor 4.80 Seegene 4.81 Sherlock Biosciences 4.82 Siemens Healthineers 4.83 Sona Nanotech 4.84 SpeeDx 4.85 Thermo Fisher Scientific Inc 4.86 Veredus Laboratories 4.87 Vircell 4.88 Visby Medical 4.89 YD Diagnostics 4.90 Zhejiang Orient Gene Biotech
5 COVID-19 Diagnostics Recent Developments 5.1 Recent Developments - Importance and How to Use This Section 5.1.1 Importance of These Developments 5.1.2 How to Use This Section 5.2 LetsGetChecked Closes $150M Funding Round 5.3 Novacyt Gets CE Mark for Multigene SARS-CoV-2 Test, Launches RUO Variant Assay 5.4 Abbott Sees Sharp Decline in COVID-19 Test Revenue 5.5 Phosphorus Diagnostics Gets EUA for DTC C19 Test, Sample Collection Kit 5.6 NY Times Explores Multiplex Testing 5.7 Hologic Banking on MDx Acquisitions 5.8 Demand for Cepheid SARS-CoV-2 Point-of-Care Tests to Continue Through 2022 5.9 DiaSorin Acquires Luminex to Broaden MDx Portfolio, Expand US Presence 5.10 LumiraDx to Go Public Through SPAC 5.11 Eurofins Test Helps to ID Mutations 5.12 Roche Sees Growing Opportunities for Diagnostics 5.13 Roche to Acquire GenMark Diagnostics for $1.8B 5.14 Fulgent Genetics is to Use COVID-19 Testing Gains to Grow Clinical Sequencing 5.15 LexaGene Syndromic Panel Platform Lets Labs Customize Targets 5.16 FDA Grants EUAs for DTC Sample Collection Kit, Two Molecular Tests 5.17 At-Home Infectious Disease Test Developer Lucira Health Goes Public
6 The Global Market for COVID-19 Diagnostics 6.1 Global Market Overview by Country 6.2 Global Market by Technology - Overview 6.3 Global Market by Product - Overview 6.4 Global Market by Channel - Overview
7 Global COVID-19 Diagnostic Markets - By Technology 7.1 PCR 7.2 PCR Multiplex 7.3 Sequencing 7.4 Antibody 7.5 Antigen
8 Global COVID-19 Diagnostic Markets - By Product 8.1 Instruments 8.2 Reagents & Kits 8.3 Extraction 8.4 Collection
9 Global COVID-19 Diagnostic Markets - By Channel 9.1 Public 9.2 Hospital 9.3 Clinic 9.4 Workplace 9.5 DTC/OTC 9.6 Wastewater
10 Appendix 10.1 U.S., Europe , Asia Approved COVID-19 Assays
For more information about this report visit https://www.researchandmarkets.com/r/th895d
Research and Markets Laura Wood , Senior Manager press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/global-covid-19-diagnostics-market-forecasts-2022-2027-time-to-market-and-preparedness-issues-301591647.html
The Aztecs center stands alone from the Mountain West on the preseason list of college football's best at the position.
Snap Inc. has never been an investor-friendly company as long as those investors weren't their founders, and the parent company of the Snapchat app made that even clearer Thursday.
Snap's 40% stock price crash on Friday after a dismal second quarter earnings report and brutal call is well warranted, one analysts explained to Yahoo Finance.
Michael Burry, who bet on the collapse of subprime credit, does not hesitate to give his opinion on market developments.
Verizon stock is moving lower after an earnings miss and dip in wireless subscriber growth.
Yahoo Finance Editor-in-Chief Andy Serwer discusses Berkshire's stake in Occidental Petroleum and what that indicates to investors.
Fed’s zigzagging policies could ultimately lead to an outcome similar to what happened in its fight against inflation four decades ago.
(Bloomberg) -- The housing market correction that’s taking hold in Canada could turn out to be its biggest in recent history, according to a new forecast from the country’s largest bank.Most Read from BloombergThree Arrows Founders Break Silence Over Collapse of Crypto Hedge FundTrump Insiders Recall How He Spurned Pleas to Act as Riot RagedTesla’s Bitcoin Dump Leaves Accounting Mystery in Its WakeAmericans Who Can’t Afford Homes Are Moving to Europe InsteadStudent Loan Borrowers Aren’t Waiting
The Dow Jones fought back. Tesla stock rocketed after Elon Musk gave an update on its "best product ever." Apple stock popped. Bitcoin fell.
Verizon is set for its worst week since October 2008, but it's sitting on must-hold support right now.
Every one of those quarterly reports has shown a growing company, despite plenty of ups and downs in the economy—and the internet. Amazon’s worst quarter came in September 2001, when the internet bubble was blowing apart. Now, though, Amazon’s streak may be coming to an end.
This money management maven doesn't mince words when it comes to what you shouldn’t be doing with your money.
Rakon (NZSE:RAK) has had a rough three months with its share price down 20%. However, stock prices are usually driven...
U.S. stocks were under pressure Friday afternoon as a disastrous quarter from Snap weighed on the broader tech sector.
Just where is the stock market going, that’s the question investors are trying to answer. The answer isn’t fully clear, though; markets have fallen for most of this year, but the last few days have seen the best trading in weeks. The problem is, investors and economists aren’t sure if we’re at a true bottom or just in the midst of a bear market rally. What happens next is anyone’s guess, but the history of bears and rallies can offer some suggestions. Looking back to the end of the Second World
ARKK ETF had a tough day, with nearly all of its holdings aside from Tesla in the red.
HSBC, one of the world’s biggest banks, became the first in China to establish an internal Communist Party committee, paving the path for global lenders to follow suit.
Q.: My wife inherited a 401(k) from my mom who died recently. Assuming this is a traditional 401(k), you are correct that whatever comes out of the account will be likely be taxable to you. Transfer your wife’s share of the money to an Inherited 401(k) with the company that held your mom’s 401(k).
GlaxoSmithKline (GSK) closed at $42.29 in the latest trading session, marking a +0.09% move from the prior day.
In this article, we discuss the 10 stocks that Jim Cramer is talking about. If you want to read about some more stocks that Jim Cramer is talking about, go directly to Jim Cramer Is Talking About These 5 Stocks. Recession fears in the United States have reached fever pitch as even veteran stock market […]